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New therapeutic options in breast cancer have improved survival but consequently increase the relevance of late complications.
Ovarian suppression/ablation and aromatase inhibitors (AI) in the adjuvant setting have improved outcome, but have clinically
important adverse effects on bone health. However, investigation and management of cancer treatment-induced bone loss (CTIBL) is
poorly defined with no national guidance. In 2004, a questionnaire was sent to over 500 breast surgeons and oncologists who treat
breast cancer within the United Kingdom. The questionnaire evaluated access to bone densitometry and specialist expertise as well as
attitudes to investigation of CTIBL and anticipated changes in the use of AI for postmenopausal early breast cancer. A total of 354
completed questionnaires were received, 47 from clinicians not currently treating breast cancer. Of the 307 evaluable questionnaires,
164 (53%) were from breast surgeons, 112 (36%) from clinical oncologists and 31 (10%) from medical oncologists. Although most
respondents recognised that CTIBL was the responsibility of the treating breast team, investigations for CTIBL are limited even
though most had adequate access to bone densitometry; 98 (32%) had not requested a DXA scan in the last 6 months and 224
(73%) had requested fewer than five scans. In all, 235 (76%) were not routinely investigating patients on AI for bone loss. A total of
277 (90%) felt that their practice would benefit from national guidelines to manage these patients, and the majority (59%) had little or
no confidence in interpreting DXA results and advising on treatment. This questionnaire has highlighted clear deficiencies in
management of CTIBL in early breast cancer. The development of national guidelines for the management of these patients and
educational initiatives for breast teams are urgently required.
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Many therapies for breast cancer are associated with cancer
treatment-induced bone loss (CTIBL). Of principle concern are
ovarian suppression in premenopausal women and aromatase
inhibitors (AI) in postmenopausal women, which both cause
marked reductions in circulating oestradiol that have significant
effects on bone physiology.
The most profound changes in bone mineral density (BMD)
occur following induction of the menopause, whether induced by
oophorectomy, irradiation, LHRH analogues or chemotherapy.
BMD can deteriorate by as much as 4.8% at the lumbar spine in
just 6 months (Leather et al, 1993) while, even in the presence of
tamoxifen, ovarian suppression with goserelin results in an
average 8% reduction in BMD over 2 years (Gnant et al, 2004).
Several recent trials have suggested the benefit of AI’s over
tamoxifen for the adjuvant therapy of postmenopausal breast
cancer patients (The ATAC Trialists’ Group, 2002, 2005; Goss et al,
2003; Coombes et al, 2004). As a consequence, long-term adjuvant
use of an AI or a tamoxifen-AI sequence is anticipated to replace 5
years of tamoxifen as the standard of care for these patients (Winer
et al, 2005).
Tamoxifen can preserve bone density in postmenopausal
women due to its mild oestrogen agonist action on bone (Love
et al, 1992) although this does not occur in premenopausal women
(Powles et al, 1996). All of the AIs have been associated with an
increased risk of fractures and bone loss of approximately 2% per
year (Lester et al, 2005). Over a 5-year period of treatment with an
AI, an average of 7–8% loss of bone is estimated, equivalent to an
average reduction in T score of  1.0 or a doubling of fracture risk
(Marshall et al, 1996).
The trial with the most mature fracture data is the ATAC
(Arimidex, Tamoxifen Alone or in Combination) trial which
reported a significantly higher risk of fracture compared to
tamoxifen at all time points on study (overall 11 vs 7.7%) (Howell,
2003) with the most marked differences in fracture rates occurring
between 18 and 24 months (Howell, 2003). Following this the
fracture rate in anastrozole-treated women plateaued and subse-
quently fell on completion of treatment.
In most studies, the effects of AI on bone are confounded by
either comparison with tamoxifen or use after pretreatment with
tamoxifen. Only one study has monitored the effect of exemestane
on bone and compared the outcomes to those taking placebo
(Lonning et al, 2005). This study suggested the effects, at least with
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sthis particular AI, were modest and reversible. After 2 years the
mean annual rate of BMD loss in the exemestane group was quite
similar to placebo in the spine (2.17 vs 1.84%, P¼NS) although
significantly greater at the hip (2.72 vs 1.48%; P¼0.024). On
withdrawal of exemestane on completion of treatment there was at
least partial recovery of BMD over the subsequent year. At present
it is uncertain whether the anabolic effect of exemestane will
compensate for the class effect of the potent AI on circulating (and
tissue) oestradiol levels, and be less detrimental to bone than
anastrozole and letrozole. Trials directly comparing the efficacy of
the different AI will hopefully clarify this issue.
Guidelines for the management of breast cancer patients at risk
of osteoporosis have been published by the American Society of
Clinical Oncology (ASCO) (Hillner et al, 2003). However, there are
no national guidelines in the UK and little or no understanding of
the current management of CTIBL in this country.
In the UK, the decision on which endocrine therapy to offer
the patient is guided by protocols agreed by the multidisciplinary
team (MDT) but the final decision left to the specialist who first
sees the patient following surgery. This is often the surgical team,
particularly in patients who do not need to see a clinical oncologist
to discuss radiotherapy. Patients due to receive chemotherapy will
be offered an endocrine therapy by their oncologist once their
course of their treatment is completed.
Similarly, follow-up for patients with surgically treated breast
carcinoma is generally shared between the oncologists and
surgeons. Typically those managed by endocrine therapy alone
are followed up by surgeons, while those requiring chemotherapy
followed up by oncologists or participate in a shared care
arrangement between the two specialties. Thus, all clinicians in
the MDT involved in need to be aware of the issues surrounding
CTIBL.
In order to facilitate development of UK guidelines we have
collated through a questionnaire survey the opinions and under-
standing of breast cancer specialists on this increasingly important
issue to facilitate development of a management strategy for breast
cancer women receiving adjuvant treatments.
MATERIALS AND METHODS
From an internet-based database, a total of 539 breast surgeons
and oncologists were highlighted as presently treating patients
with breast cancer. Anonymous questionnaires were sent with a
covering letter and prepaid return envelope to each of these
specialists in May 2004. Further questionnaires were sent to
nonresponders in July 2004. The full questionnaire is available on
request from the authors.
The questionnaire asked specific questions about the number of
breast cancer patients treated per year. Each specialist was asked if
they had access to DXA scanning and an osteoporosis specialist,
the waiting times for a scan and an estimate of the number of scans
performed in the past 6 months. The presence or absence of local
guidelines for the monitoring of bone density in breast cancer
patients was also determined. Confidence in interpreting DXA scan
results and acting upon results was requested. The percentage of
patients that are currently prescribed an AI in the adjuvant setting
and predicted use in 2–3 years time was ascertained. Specialists
were also asked their management of various clinical scenarios
associated with CTIBL including both AI use and ovarian
suppression. This provided information on the awareness of
specialists and the degree of interest in investigating patients. In
terms of patient management, specialists were asked which
treatments they would offer to patients taking an AI or receiving
ovarian suppression with varying levels of BMD (normal,
osteopaenia, osteoporosis). The time points when specialists
would request repeat DXA scans were also asked. Finally, we
asked if specialists felt that their practice would benefit from
national guidelines for the diagnosis and management of bone loss
in early breast cancer patients.
Questions related to confidence in interpreting scan results or
interest in investigating patients in a given clinical scenario were
answered using a 5-point scale from 1 (not at all confident/not at
all interested) to 5 (very confident/very interested). For some
questions these scores were then summarised into low (1 and 2),
intermediate (3) and high (4 and 5) for the purposes of reporting
and analysis (the full questionnaire is available on line/on request).
RESULTS
Out of 539 specialists, 354 (66%) returned the questionnaire; 307
were currently treating breast cancer. Of these 307 questionnaires,
164 (53%) were from breast surgeons, 112 (36%) from clinical
oncologists and 31 (10%) from medical oncologists.
Access to and waiting times for DXA
Access to bone densitometry was generally good with 245 (80%) of
specialists having a hip/spine or a peripheral DXA machine either
locally or within their hospital. The remaining 62 (20%) either did
not know or did not have access to a bone densitometer. Many
specialists were able to obtain a DXA scan within 12 weeks,
however, almost 20% of specialists aware of the waiting times were
already experiencing delays of more than 6 months.
Access to osteoporosis specialist
Only 52 (17%) of specialists had local guidelines for the screening
and management of breast cancer patients for bone loss. Most
specialists had ready access to an osteoporosis/bone health expert,
however, 111 (36%) did not.
Responsibility for monitoring CTIBL
Specialists were asked who should be responsible for the
monitoring of patients at risk from bone loss. Choices included;
general practitioner, oncologist, breast surgeon and osteoporosis
specialist.
Oncologists were considered to be the most appropriate
specialty to take responsibility for monitoring and treating bone
issues with 174 (57%) believing that they should be responsible for
monitoring and treating the bone effects of adjuvant therapies.
This was largely independent of the respondents specialty with
91 (55%) of breast surgeons and 60 (54%) of clinical oncologists
recommending follow-up by an oncologist. Slightly more medical
oncologists (23, 74%) recommended oncological follow-up.
In all, 57 (19%) indicated that the responsibility should be
shared between the breast surgeon and oncologist. Only 43 (14%)
of specialists considered that management was the responsibility
of the general practitioner.
Number of scans requested
Monitoring of bone health is not occurring systematically. A total
of 98 (32%) had not requested a single DXA scan in the previous 6
months and 224 (73%) had requested fewer than five scans. A total
of 235 (76%) are not routinely investigating patients for bone loss
while taking an AI.
Interpretation of results
A question was asked about the confidence of breast cancer
specialists in the interpretation of DXA scans. The response was
graded from 1 to 5 (1¼not at all confident, 5¼very confident).
Only 70 (23%) expressed confidence with an answer of 4 or 5. A
total of 181 (59%) responded with an answer of 1 or 2 and of these
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s138 (45%) were not at all confident (see Figure 1). Medical
oncologists expressed the most confidence with 39% giving a score
of 4–5.
Current and future use of AI’s
Specialists were asked about the proportion of patients that they
prescribed AI’s to at the time of the questionnaire and their
anticipated use in 2–3 years time. Figure 2 shows that as of 2004
most specialists treat only approximately 5–10% of their patients
with AI’s. It is clear however that this is anticipated to change
considerably over the next few years as treatment guidelines evolve
and funding issues are resolved.
The interest in investigating patients at risk from bone loss
Specialists were asked how interested they would be to investigate
various patients on a scale of 1–5 (1¼not at all keen, 5¼very
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Scale of confidence 
(1=not at all confident, 5=very confident)
Medical oncologists 8                     4                     7 10 2
Clinical oncologists 41 17 24 22 8
Breast surgeons 89 22 25 19 9
1                     2                     3 4 5
14%
45%
 
18% 
17%
 
6%
Figure 1 The confidence of breast cancer specialists at the interpretation of DXA based on the question: On a scale of 1–5 how confident are you in
interpreting DEXA scan results? (1¼not at all confident, 5¼very confident).
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% of patients prescribed AI's
Now 2–3 years
Now 8.5 28.0 33.9 16.9 7.5 1.6 3.6
2–3 years 1.1 1.1 10.3 11.8 34.2 22.8 18.8
0 1–5 5–10 10–20 20–50 50–75 > 75
35 specialists gave no response for 2–3 years time 
Figure 2 Estimated proportion of patients prescribing AI at the time of the survey and in 2–3 years time based on the question: What proportion of your
ERþearly breast cancer patients would you prescribe aromatase inhibitors to either instead of tamoxifen or after an initial course of tamoxifen? In all, 35
specialists gave no response for 2–3 years time.
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skeen). For the purposes of reporting and analysis, these scores
were summarised into a low (1 and 2), intermediate (3) and high
(4 and 5) degree of interest. The patients most at risk from future
bone loss and the degree of interest in investigating them is
summarised in Table 1.
Postmenopausal women commencing on an AI In all, 154 (50%)
of specialists responded with low degree of interest in obtaining a
baseline BMD value prior to commencing on an AI. Furthermore,
only 94 (31%) showed a high degree of interest in investigating
these patients.
Postmenopausal woman after 2 years of an AI A greater number
of specialists recognised a need for bone densitometry after 2 years
of an AI with 141 (46%) recording a response of 4 or 5. However,
89(29%) gave a response of 1 or 2.
At 2 years after a premature menopause induced by chemotherapy
or ovarian ablation Specialists were most keen to investigate
patients after a treatment-induced premature menopause with 161
(53%) expressing a high degree of interest.
Premenopausal woman starting an LHRH agonist for 2–3
years Few were interested in investigating premenopausal
women at the start of treatment with an LHRH agonist with 154
(50%) recording either 1 or 2.
The treatments and lifestyle advice offered to patients
taking AI’s
Figures 3A–C show the percentage of specialists who offered a
treatment to patients taking an AI with normal BMD, osteopenia
and osteoporosis. Only 39 (12.7%) would prescribe patients
calcium and vitamin D supplements to patients with normal
BMD. Furthermore, 100 (33%) of specialists did not offer a
bisphosphonate to patients with osteoporosis. In all, 79 (26%) of
specialists would give no special recommendations to their
patients who have been diagnosed with osteopososis while taking
an AI. These patients were not offered any lifestyle advice or
medications to treat bone loss.
Figure 4 shows when follow-up DXA scans would have been
requested in these patients. Only 71 (23%) would repeat a DXA
scan after 2 years treatment with an AI if they were found to have
normal BMD at baseline.
Views on the development of a national guideline
Most specialists felt that they would benefit from national
guidelines for the management of these patients. In total, 277
(90%) specialists would support the development of a national
guideline.
DISCUSSION
Early reports from clinical trials of AI’s vs tamoxifen have so
far favoured AI’s in terms of disease-free survival, risk of
contralateral disease and toxicity profile. As a consequence these
clinical trials and others still yet to report are likely to account
for an increasing use of AI’s in the next few years. This increase
in breast cancer patients taking AI’s, along with increasing use of
treatments in young women that result in a premature menopause,
is likely to put more women at risk from bone loss and therefore
fracture.
This questionnaire has demonstrated that waiting times for bone
densitometry is usually greater than 12 weeks, and in some centres
patients may wait as long as 6 months. Of specialists, 36% had no
access to an osteoporosis expert and only 17% had local guidelines
for the screening and management of patients at risk from bone
loss. At present breast cancer specialists within the UK request
very few DXA scans and only 24% are actively investigating their
patients for CTIBL. The ability to interpret DXA scans is also a
problem with only 23% expressing a high level of confidence.
Overall the degree of interest in investigating patients at risk
from CTIBL is low. The introduction of a national guideline of how
to manage CTIBL may increase awareness but also open the door
to improved DXA scanning facilities.
Monitoring of CTIBL has implications for the follow-up
arrangements for patients with breast cancer. Most specialists
consider that the responsibility for monitoring bone loss over the
5–6 years of adjuvant therapy rests with the breast cancer team.
However, National Institute of Clinical Excellence (NICE) clinical
outcomes guidance recommends discharge from follow-up at 3
years (National Institute of Clinical Excellence, 2002).
In the community, general practitioners are responsible for
identifying patients at risk from osteoporosis and will often refer
to an osteoporosis specialist for evaluation and advice on
management rather than access BMD measurements directly and
decide on treatments. Treatment-induced bone loss however,
as occurs in breast cancer management, is an uncommon clinical
scenario for a general practitioner and, along with issues such
as duration of endocrine treatment, likely to be considered the
responsibility of the breast team. The development of national
guidance in preparation by the National Osteoporosis Society is
expected to clarify these lines of responsibility.
It is likely that the sequential use of AI’s following a period of
tamoxifen will have a less pronounced effect on bone density
because of the bone-preserving action of tamoxifen. Estimated
bone loss after 5 years of an AI is approximately 7%, however, this
may be as little as 2% with tamoxifen-AI sequential therapy. The
degree of bone loss expected in a postmenopausal woman over this
time period is also approximately 2–3%.
CTIBL is clearly an important issue of international relevance;
however, there have been very few published recommendations for
the management of these patients (Hillner et al, 2003; Coleman,
2004; Lipton, 2004; Theriault, 2004). In 2003, the American Society
Table 1 The degree of interest in investigating patients at risk from bone loss based on the question: On a scale of 1–5 how keen would you be to
investigate the following breast cancer patients for possible osteoporosis? (1¼not at all keen, 5¼very keen)
Degree of interest investigating patient (1¼not at all interested, 5¼very interested)
1–2 3 4–5
Postmenopausal woman commencing an AI 154 (50%) 59 (19%) 94 (31%)
Postmenopausal woman after 2 years of an AI 89 (29%) 77 (25%) 141 (46%)
Two years after a premature menopause 90 (29%) 56 (18%) 161 (53%)
Premenopausal woman about to start 2–3 years of
an LHRH agonist
154 (50%) 61 (20%) 92 (30%)
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sfor Clinical Oncology (ASCO) published a guideline for the
monitoring and treatment of bone loss associated with breast
cancer treatment (Hillner et al, 2003). Calcium and vitamin D
supplements were recommended to all patients taking an AI and
bisphosphonates for patients with osteoporosis. Educational
needs, availability of DXA facilities and clinical protocols are
likely to vary from country to country but common principles exist
and informal discussion with breast cancer specialists in Europe
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Figure 3 What treatment or lifestyle recommendations would you make in the following clinical situations? (A) Patients with normal BMD taking an AI,
(B) Patients with osteopenia taking an AI and (C) Patients with osteoporosis taking an AI.
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of CTIBL (Coleman, personal communication).
The patients most at risk of bone loss include postmenopausal
women taking AI’s, premenopausal women taking LHRH agonists
and those with a chemotherapy-induced early menopause. These
patients should all be offered calcium and vitamin supplements
as well as lifestyle advice such as regular exercise, avoidance of
smoking and a healthy diet. Patients over the age of 65 years on a
tamoxifen-AI sequence and all patients taking an AI should have a
baseline DXA scan. Patients with osteoporosis should be treated
with a bisphosphonate known to reduce the incidence of
osteoporotic fracture and those with osteopenia have their bone
densitometry repeated on a yearly basis and treatment introduced
for rapid bone loss or development of osteoporosis.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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Figure 4 The percentage of specialists who would repeat DXA scans of
normal, osteopenic and osteoporotic patients taking AI’s when asked: How
often would you repeat the DEXA scan in such patients?.
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